Antileukemic efficacy of continuous (cont) vs discontinuous (disc) dexamethasone for two xenografted patient ALL samples. A, Representative data from mice engrafted with one of the 5 samples that showed equal efficacy with the two dexamethasone regimens (p=0.9). Mice were treated from days 7 – 50. Survival was significantly longer with both dexamethasone regimens than with no dexamethasone (n=5, p=0.02). B, Mice engrafted with a single patient sample show superior anti-leukemic efficacy with cont dexamethasone vs disc dexamethasone (p=0.002). Mice were treated from days 21-91.